Company Profile

Industry Sector: Medical Devices

Company Overview: We develop state-of-the-art evoked-response methodology directed towards new clinical uses. Our Research Director has an excellent track record for these goals, a record established first in academe, and now sustained in the invention and development of Q-Sequence Deconvolution (QSD). QSD has detected brain activity never previously observed, nor even suspected. We collaborate with clinicians and equipment manufacturers to demonstrate the clinical uses.

Target Market(s): Major hospitals and clinics

Management

Leadership:

Virginia H. Meyer, J.D.
President

Don L. Jewett, M.D., D.Phil. (Oxon)
Vice President and Research Director

Key Value Drivers

Technology*: Q-Sequence Deconvolution (QSD) is a novel, patented algorithm that permits detection of evoked-response waveforms that are overlapped in time because the response is longer than the time between stimuli.

Competitive Advantage: QSD permits stimulus rates to be increased with the consequence that sensitivity to pathology is increased, while waveform accuracy is maintained. When the stimulus rate is above sensory fusion, new brain activity is evident (A-waves). No other methods show this phenomenon, because of their inherent limitations.

Plan & Strategy: Collaborations with clinicians and equipment manufacturers, to determine and document the unique advantages of QSD.

Product Development:

Memory retention under light anesthesia
Coma Monitoring and Analysis
Newborn Screening
Cortical development during childhood
Attention Deficit Disorder
Traumatic Brain Injury, concussion
Epilepsy treatment
Neuronal Source Localization